title: Glutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications.
abstract: Glutamate, a nonessential amino acid, is the major excitatory neurotransmitter in the central nervous system. As such, glutamate has been shown to play a role in not only neural processes, such as learning and memory, but also in bioenergetics, biosynthetic and metabolic oncogenic pathways. Glutamate has been the target of intense investigation for its involvement not only in the pathogenesis of benign neurodegenerative diseases (NDDs) such as Parkinson's disease, Alzheimer's disease, schizophrenia, multiple sclerosis, and amyotropic lateral sclerosis (ALS), but also in carcinogenesis and progression of malignant diseases. In addition to its intracellular activities, glutamate in secreted form is a phylogenetically conserved cell signaling molecule. Glutamate binding activates multiple major receptor families including the metabotropic glutamate receptors (mGluRs) and ionotropic glutamate receptors (iGluRs), both of which have been implicated in various signaling pathways in cancer. Inhibition of extracellular glutamate release or glutamate receptor activation via competitive or non-competitive antagonists decreases growth, migration and invasion and induces apoptosis in breast cancer, melanoma, glioma and prostate cancer cells. In this review, we discuss the current state of glutamate signaling research as it relates to benign and malignant diseases. In addition, we provide a synopsis of clinical trials using glutamate antagonists for the treatment of NDD and malignant diseases. We conclude that in addition to its potential role as a metabolic biomarker, glutamate receptors and glutamate-initiated signaling pathways may provide novel therapeutic opportunities for cancer.
authors: Departments of Cancer Genetics and Urology, Center for Genetics and Pharmacology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
authors: Stacey S
authors: SS
authors: Willard
authors: Shahriar
authors: S
authors: Koochekpour
mesh_terms: D002986:Clinical Trials as Topic; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D005260:Female; D018698:Glutamic Acid / Q000502:physiology*; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000503:physiopathology*; D019636:Neurodegenerative Diseases / Q000503:physiopathology*; D018377:Neurotransmitter Agents; D058468:Receptors, Ionotropic Glutamate / Q000502:physiology*; D018094:Receptors, Metabotropic Glutamate / Q000502:physiology*; D015398:Signal Transduction / Q000502:physiology*
chemical_list: D018691:Excitatory Amino Acid Antagonists; D018377:Neurotransmitter Agents; D058468:Receptors, Ionotropic Glutamate; D018094:Receptors, Metabotropic Glutamate; D018698:Glutamic Acid
keywords: GRM1a; Glutamate; brain; breast; cancer; glioma.; iGluR; mGluR; mGluR1a; melanoma; prostate; signaling
references: Curr Opin Psychiatry. 2012 Nov;25(6):542-50
references: 22992546
references: Curr Biol. 1998 Oct 22;8(21):1195-8
references: 9799739
references: CNS Neurol Disord Drug Targets. 2010 Nov;9(5):574-95
references: 20632969
references: Harv Rev Psychiatry. 2010 Sep-Oct;18(5):293-303
references: 20825266
references: Handb Exp Pharmacol. 2012;(213):267-95
references: 23027419
references: Trends Neurosci. 2003 Oct;26(10):543-9
references: 14522147
references: Biochem Biophys Res Commun. 2010 Jan 1;391(1):91-5
references: 19896463
references: J Cell Physiol. 2011 Oct;226(10):2484-93
references: 21792905
references: Clin Cancer Res. 2011 Nov 15;17(22):7080-92
references: 21844014
references: Mol Cancer Ther. 2008 Oct;7(10):3129-40
references: 18852116
references: Nat Neurosci. 2003 Nov;6(11):1153-61
references: 14528310
references: J Physiol. 2012 May 15;590(10):2213-6
references: 22351632
references: J Cell Sci. 2000 Jun;113 ( Pt 11):1851-6
references: 10806096
references: Biochem Pharmacol. 2008 Mar 1;75(5):997-1006
references: 18164691
references: Cell Signal. 2006 Aug;18(8):1279-86
references: 16305822
references: Adv Exp Med Biol. 1988;226:595-608
references: 3407534
references: Histochem Cell Biol. 2009 Oct;132(4):435-45
references: 19526364
references: Science. 2011 Aug 26;333(6046):1157-60
references: 21798893
references: Ment Retard Dev Disabil Res Rev. 2001;7(4):287-95
references: 11754524
references: Acta Pharmacol Sin. 2009 Apr;30(4):379-87
references: 19343058
references: Eur J Neurosci. 2003 May;17(10):2106-18
references: 12786977
references: Arch Gen Psychiatry. 2006 Aug;63(8):856-64
references: 16894061
references: Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15219-24
references: 21896768
references: Annu Rev Pharmacol Toxicol. 1997;37:205-37
references: 9131252
references: Trends Neurosci. 2000 Feb;23(2):80-8
references: 10652549
references: Pigment Cell Res. 2000 Jun;13(3):158-64
references: 10885674
references: Clin Cancer Res. 2012 Nov 1;18(21):5888-901
references: 23072969
references: Nat Med. 2007 Sep;13(9):1102-7
references: 17767166
references: Nat Med. 2006 Jul;12(7):824-8
references: 16767099
references: Trends Neurosci. 2008 May;31(5):234-42
references: 18395805
references: Cancer Res. 2001 Sep 15;61(18):6674-8
references: 11559533
references: Nature. 2011 Jun 29;474(7353):609-15
references: 21720365
references: Cancer Discov. 2011 Jul;1(2):137-43
references: 21984974
references: Neurology. 2011 Apr 12;76(15):1344-52
references: 21482951
references: Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16342-7
references: 22988116
references: Int J Clin Exp Med. 2008;1(4):338-44
references: 19079679
references: Nature. 1997 Mar 20;386(6622):284-8
references: 9069287
references: J Neurosci. 2008 Jan 9;28(2):543-7
references: 18184796
references: Nature. 2010 Aug 12;466(7308):869-73
references: 20668451
references: Science. 2008 Sep 26;321(5897):1807-12
references: 18772396
references: Neuropsychopharmacology. 2012 Jan;37(1):4-15
references: 21956446
references: Eur J Pharmacol. 2013 Jan 5;698(1-3):6-18
references: 23123057
references: Expert Opin Investig Drugs. 2009 Aug;18(8):1061-83
references: 19555299
references: FEBS Lett. 1997 Jul 21;412(1):183-9
references: 9257717
references: Nat Genet. 2009 Oct;41(10):1127-32
references: 19718025
references: J Dermatol. 2010 Jul;37(7):635-46
references: 20629830
references: Curr Drug Targets. 2007 Jan;8(1):169-84
references: 17266540
references: Science. 2006 Oct 13;314(5797):268-74
references: 16959974
references: Oncogene. 2013 Sep 12;32(37):4366-76
references: 23085756
references: Neuropharmacology. 2008 Sep;55(4):396-402
references: 18554669
references: Drugs. 2012 Jul 9;72(10):1313-33
references: 22731961
references: Pharmacol Rev. 2011 Mar;63(1):35-58
references: 21228260
references: J Neurooncol. 2004 Nov;70(2):245-54
references: 15674481
references: Pharmacol Biochem Behav. 2012 Feb;100(4):850-4
references: 21315104
references: CNS Drugs. 2012 Dec;26(12):1017-32
references: 23114872
references: Clin Cancer Res. 2012 Aug 15;18(16):4240-6
references: 22648273
references: J Invest Dermatol. 1998 Mar;110(3):247-52
references: 9506443
references: J Child Neurol. 1999 Mar;14(3):173-9
references: 10190269
references: Nat Genet. 2010 Nov;42(11):1021-6
references: 20890276
references: J Neurochem. 2008 Apr;105(2):287-95
references: 18284616
references: Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3759-64
references: 17360426
references: Asian J Androl. 2013 Mar;15(2):212-3
references: 23314660
references: J Clin Psychiatry. 2013 Mar;74(3):e05
references: 23561237
references: J Cell Physiol. 2007 Dec;213(3):589-602
references: 17786953
references: Neurology. 1996 Dec;47(6 Suppl 4):S233-41
references: 8959995
references: Pigment Cell Melanoma Res. 2012 May;25(3):331-42
references: 22273393
references: J Neurosci. 2005 Mar 9;25(10):2741-52
references: 15758184
references: Neurosci Biobehav Rev. 2005;29(4-5):571-625
references: 15890404
references: Pharmacol Rev. 2010 Sep;62(3):405-96
references: 20716669
references: Nat Genet. 2003 May;34(1):108-12
references: 12704387
references: J Biol Chem. 2000 Dec 8;275(49):38213-20
references: 10982802
references: Proc Natl Acad Sci U S A. 2001 May 22;98(11):6372-7
references: 11331750
references: Front Biosci. 2006 Sep 01;11:2081-92
references: 16720295
references: Biochem Biophys Res Commun. 2006 Nov 17;350(2):463-71
references: 17011514
references: Pigment Cell Melanoma Res. 2010 Feb;23(1):103-11
references: 19843246
references: Trends Neurosci. 2004 Jul;27(7):370-7
references: 15219735
references: Cell. 2009 Apr 3;137(1):159-71
references: 19345194
references: Mol Pharmacol. 2013 Apr;83(4):770-80
references: 23303475
references: Oncogene. 2008 Dec 4;27(57):7162-70
references: 18776920
references: Neuron. 1998 Oct;21(4):717-26
references: 9808459
references: Genome Biol. 2007;8(2):206
references: 17316461
references: Methods Enzymol. 2013;520:257-79
references: 23332704
references: Cancer Res. 1999 Sep 1;59(17):4383-91
references: 10485487
references: Neuron. 1998 Oct;21(4):707-16
references: 9808458
references: Drugs Today (Barc). 2012 Jul;48(7):469-78
references: 22844658
references: Behav Brain Res. 2012 Feb 1;227(1):276-86
references: 22085878
references: Neuropharmacology. 2013 Jan;64:337-46
references: 22992331
references: J Neurosci. 2002 Oct 15;22(20):9134-41
references: 12388621
references: J Comp Neurol. 2004 Aug 2;475(4):551-63
references: 15236236
references: Nat Genet. 2011 May;43(5):442-6
references: 21499247
references: J Surg Oncol. 2009 Feb 1;99(2):114-8
references: 19034932
references: Anticancer Res. 2009 Jun;29(6):2195-204
references: 19528481
references: Expert Rev Anticancer Ther. 2010 Nov;10(11):1735-51
references: 21080801
references: Nat Rev Neurol. 2011 Oct 11;7(11):639-49
references: 21989247
references: Nat Genet. 2011 Dec 11;44(1):47-52
references: 22158541
references: Neurosci Lett. 1994 Aug 15;177(1-2):95-9
references: 7824190
references: J Invest Dermatol. 1996 May;106(5):1145-51
references: 8618055
references: Neuropharmacology. 1995 Jan;34(1):1-26
references: 7623957
references: J Clin Invest. 2008 Sep;118(9):3051-64
references: 18725989
references: Cancer Biol Ther. 2009 Oct;8(19):1791-7
references: 19770591
references: J Biol Chem. 2003 Apr 25;278(17):15040-8
references: 12576483
references: Biol Psychiatry. 2000 Feb 15;47(4):351-4
references: 10686270
references: Nature. 2012 Apr 04;486(7403):395-9
references: 22495314
references: Nat Genet. 2012 Sep;44(9):1006-14
references: 22842228
references: Mol Cancer. 2011 Oct 11;10:128
references: 21988793
references: Neurochem Int. 2012 Oct;61(5):731-8
references: 22749857
references: Nature. 2008 Oct 23;455(7216):1061-8
references: 18772890
references: Clin Exp Metastasis. 2009;26(7):781-7
references: 19526315
references: Expert Opin Investig Drugs. 2005 Dec;14(12):1487-96
references: 16307489
references: J Neurotrauma. 2004 Jun;21(6):754-74
references: 15253803
references: Am J Cancer Res. 2012;2(6):620-57
references: 23226612
references: Cancer Genet. 2012 Dec;205(12):613-21
references: 23238284
references: Glia. 2011 Aug;59(8):1181-9
references: 21192095
references: Oncogene. 2011 Jan 6;30(1):43-53
references: 20802520
references: Proc Natl Acad Sci U S A. 2001 May 22;98(11):5947-8
references: 11371628
references: Autism Res. 2009 Dec;2(6):322-33
references: 19998356
references: Cancer Res. 2007 Mar 1;67(5):2298-305
references: 17332361
references: Mol Neurobiol. 2004 Feb;29(1):61-71
references: 15034223
references: J Biol Chem. 1996 Nov 8;271(45):28612-6
references: 8910492
references: Anticancer Res. 2009 Jan;29(1):371-7
references: 19331175
references: Nat Genet. 2011 Sep 25;43(11):1119-26
references: 21946352
references: Breast Cancer Res Treat. 2012 Apr;132(2):565-73
references: 21681448
references: Nat Med. 2008 Jun;14(6):629-32
references: 18469825
references: J Invest Dermatol. 2010 Sep;130(9):2240-9
references: 20505744
references: J Natl Cancer Inst. 1999 Nov 17;91(22):1922-32
references: 10564676
references: J BUON. 2012 Apr-Jun;17(2):209-22
references: 22740196
references: Bioorg Med Chem. 2012 Sep 15;20(18):5642-8
references: 22892214
references: Neuron. 2000 Apr;26(1):143-54
references: 10798399
references: Clin Cancer Res. 2009 Jun 1;15(11):3896-902
references: 19458050
references: PLoS One. 2011;6(6):e20405
references: 21731612
references: Int J Cancer. 2010 Jun 1;126(11):2542-52
references: 19824040
references: Curr Opin Neurobiol. 1995 Jun;5(3):342-9
references: 7580157
references: Curr Opin Neurobiol. 2000 Jun;10(3):370-4
references: 10851183
references: J Neurosci. 1998 Nov 1;18(21):8751-7
references: 9786982
references: J Neurophysiol. 2010 Jul;104(1):439-48
references: 20463192
references: Nat Med. 2001 Sep;7(9):1010-5
references: 11533703